Posted by Michael Wonder on 26 Jul 2021
Aadi Bioscience announces FDA acceptance and priority review for the new drug application of Fyarro for the treatment of advanced malignant PEComa
26 July 2021 - FDA grants priority review and sets PDUFA target action date of 26 November 2021
Aadi Bioscience today announced that the U.S. FDA has accepted the company’s new drug application for its nanoparticle albumin-bound mTOR inhibitor, Fyarro (sirolimus albumin-bound nanoparticles for injectable suspension, nab-sirolimus ABI-009;) and has granted the company priority review status with a Prescription Drug User Fee Act target action date of 26 November 2021.
